Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Povidone-iodine Lavage in Stage IVA Thymic Malignancies
NCT04371458Phase 2Withdrawn
- Sponsor
- Yale University
- Start
- Jul 2020
- Primary completion
- Jul 2025
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of povidone-iodine in thymoma and thymic carcinoma (TC), sponsored by Yale University. Primary endpoint: Progression free survival at 5 years. Planned start Jul 2020; status: withdrawn.
02
Drugs
povidone-iodine
03
Conditions
thymomathymic carcinoma (TC)
Beyond the preview
Go deeper on NCT04371458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04371458.